Fresenius Medical Care (NYSE:FMS) Shares Gap Up – Should You Buy?

Fresenius Medical Care AG (NYSE:FMS)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $24.73, but opened at $25.85. Fresenius Medical Care shares last traded at $25.74, with a volume of 96,490 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Truist Financial increased their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

The stock’s 50 day moving average price is $24.14 and its two-hundred day moving average price is $22.65. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $14.05 billion, a price-to-earnings ratio of 19.79, a PEG ratio of 0.76 and a beta of 0.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Callan Family Office LLC purchased a new stake in shares of Fresenius Medical Care during the 4th quarter worth approximately $502,000. Callan Capital LLC acquired a new position in Fresenius Medical Care during the fourth quarter worth $297,000. Sanctuary Advisors LLC purchased a new stake in Fresenius Medical Care during the fourth quarter worth $983,000. ABC Arbitrage SA acquired a new stake in Fresenius Medical Care in the fourth quarter valued at $4,215,000. Finally, Verition Fund Management LLC purchased a new position in shares of Fresenius Medical Care in the third quarter valued at $237,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.